|
1
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
|
|
2
|
Mougiakakos D, Choudhury A, Lladser A,
Kiessling R and Johansson CC: Regulatory T cells in cancer. Adv
Cancer Res. 107:57–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Banerjee A, Vasanthakumar A and
Grigoriadis G: Modulating T regulatory cells in cancer: how close
are we? Immunol Cell Biol. 91:340–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang J, Wu C and Lu B: Cytokine-induced
killer cells promote antitumor immunity. J Transl Med. 11:832013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sangiolo D, Martinuzzi E, Todorovic M, et
al: Alloreactivity and anti-tumor activity segregate within two
distinct subsets of cytokine-induced killer (CIK) cells:
implications for their infusion across major HLA barriers. Int
Immunol. 20:841–848. 2008. View Article : Google Scholar
|
|
8
|
Pievani A, Borleri G, Pende D, Moretta L,
Rambaldi A, Golay J and Introna M: Dual-functional capability of
CD3+CD56+CIK cells, a T-cell subset that
acquires NK function and retains TCR-mediated specific
cytotoxicity. Blood. 118:3301–3310. 2011.PubMed/NCBI
|
|
9
|
Lu X, Zhu A, Cai X, Jia Z, Han W, Ma L,
Zhou M, Qian K, Cen L and Chen B: Role of NKG2D in cytokine-induced
killer cells against multiple myeloma cells. Cancer Biol Ther.
13:623–629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Introna M, Franceschetti M, Ciocca A,
Borleri G, Conti E, Golay J and Rambaldi A: Rapid and massive
expansion of cord blood-derived cytokine-induced killer cells: an
innovative proposal for the treatment of leukemia relapse after
cord blood transplantation. Bone Marrow Transplant. 38:621–627.
2006. View Article : Google Scholar
|
|
11
|
Huang WR, Gao CJ, Zhang BL, Jin HJ and Da
WM: Activation and cytotoxicity of bone marrow immunocytes by using
various cytokines. J Exp Hematol. 9:48–51. 2001.(In Chinese).
|
|
12
|
Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu
XF and Wang HX: Cytokine-induced killer cells in the treatment of
patients with solid carcinomas: a systematic review and pooled
analysis. Cytotherapy. 14:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hontscha C, Borck Y, Zhou H, Messmer D and
Schmidt-Wolf IG: Clinical trials on CIK cells: first report of the
international registry on CIK cells (IRCC). J Cancer Res Clin
Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thanendrarajan S, Nowak M, Abken H and
Schmidt-Wolf IG: Combining cytokine-induced killer cells with
vaccination in cancer immunotherapy: more than one plus one? Leuk
Res. 35:1136–1142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Yu JP, Cao S, Wei F, Zhang P, An XM,
Huang ZT and Ren XB: CD4+CD25+regulatory T
cells decreased the antitumor activity of cytokine-induced killer
(CIK) cells of lung cancer patients. J Clin Immunol. 27:317–326.
2007.
|
|
16
|
Schmidt J, Eisold S, Buchler MW and Marten
A: Dendritic cells reduce number and function of
CD4+CD25+cells in cytokine-induced killer
cells derived from patients with pancreatic carcinoma. Cancer
Immunol Immunother. 53:1018–1026. 2004.PubMed/NCBI
|
|
17
|
Li H, Ren XB, Zhang P, An XM, Liu H and
Hao XS: Dendritic cells reduce the number and function of
CD4+CD25+cells in cytokine-induced killer
cells. Chin Med J. 85:3134–3138. 2005.(In Chinese).
|
|
18
|
Miao L, Run-Ming J and Yi J: T-Bet
mediated anti-neoplastic effects of dendritic cell-cytokine induced
killer cells in vitro. Iran J Pediatr. 22:43–51. 2012.PubMed/NCBI
|
|
19
|
Bonanno G, Iudicone P, Mariotti A, et al:
Thymoglobulin, interferon-γ and interleukin-2 efficiently expand
cytokine-induced killer (CIK) cells in clinical-grade cultures. J
Transl Med. 8:1292010.
|
|
20
|
Lin G, Wang J, Lao X, et al: Interleukin-6
inhibits regulatory T cells and improves the proliferation and
cytotoxic activity of cytokine-induced killer cells. J Immunother.
35:337–343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng SG, Wang J, Wang P, Gray JD and
Horwitz DA: IL-2 is essential for TGF-beta to convert naive
CD4+CD25−cells to
CD25+Foxp3+regulatory T cells and for
expansion of these cells. J Immunol. 178:2018–2027. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shevach EM: Application of IL-2 therapy to
target T regulatory cell function. Trends Immunol. 33:626–632.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pandiyan P, Zheng L, Ishihara S, Reed J
and Lenardo MJ:
CD4+CD25+Foxp3+regulatory T cells
induce cytokine deprivation-mediated apoptosis of effector
CD4+T cells. Nat Immunol. 8:1353–1362. 2007.
|
|
24
|
Matsuoka K, Koreth J, Kim HT, et al:
Low-dose interleukin-2 therapy restores regulatory T cell
homeostasis in patients with chronic graft-versus-host disease. Sci
Transl Med. 5:179ra432013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang JC, Sherry RM, Steinberg SM, et al:
Randomized study of high-dose and low-dose interleukin-2 in
patients with metastatic renal cancer. J Clin Oncol. 21:3127–3132.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bluestone JA: The yin and yang of
interleukin-2-mediated immunotherapy. N Engl J Med. 365:2129–2131.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Antony PA and Restifo NP:
CD4+CD25+T regulatory cells, immunotherapy of
cancer, and interleukin-2. J Immunother. 28:120–128.
2005.PubMed/NCBI
|
|
28
|
Deshpande P, Cavanagh MM, Le Saux S, Singh
K, Weyand CM and Goronzy JJ: IL-7- and IL-15-mediated TCR
sensitization enables T cell responses to self-antigens. J Immunol.
190:1416–1423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldstein JD, Perol L, Zaragoza B, Baeyens
A, Marodon G and Piaggio E: Role of cytokines in thymus- versus
peripherally derived-regulatory T cell differentiation and
function. Front Immunol. 4:1552013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heninger AK, Theil A, Wilhelm C, Petzold
C, Huebel N, Kretschmer K, Bonifacio E and Monti P: IL-7 abrogates
suppressive activity of human
CD4+CD25+FOXP3+regulatory T cells
and allows expansion of alloreactive and autoreactive T cells. J
Immunol. 189:5649–5658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Finke S, Trojaneck B, Lefterova P, et al:
Increase of proliferation rate and enhancement of antitumor
cytotoxicity of expanded human
CD3+CD56+immunologic effector cells by
receptor-mediated transfection with the interleukin-7 gene. Gene
Ther. 5:31–39. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao N, Zhao MF, Rajbhandary S, Lu WY, Zhu
HB, Xiao X, Deng Q and Li YM: Effects of humanized interleukin 21
on anti-leukemic activity of cytokine induced killer cells and the
mechanism. Chin J Hematol. 33:823–828. 2012.(In Chinese).
|
|
33
|
Rettinger E, Kuci S, Naumann I, et al: The
cytotoxic potential of interleukin-15-stimulated cytokine-induced
killer cells against leukemia cells. Cytotherapy. 14:91–103. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rettinger E, Meyer V, Kreyenberg H, et al:
Cytotoxic capacity of IL-15-stimulated cytokine-induced killer
cells against human acute myeloid leukemia and rhabdomyosarcoma in
humanized preclinical mouse models. Front Oncol. 2:322012.
View Article : Google Scholar
|
|
35
|
Tao Q, Chen T, Tao L, Wang H, Pan Y, Xiong
S and Zhai Z: IL-15 improves the cytotoxicity of cytokine-induced
killer cells against leukemia cells by upregulating CD3+CD56+ cells
and downregulating regulatory T cells as well as IL-35. J
Immunother. 36:462–467. 2013.PubMed/NCBI
|
